ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,101.01
-0.30%
US Tech 100
17,261.20
-0.28%
다우존스 지수
38,254.16
-0.34%
Bitcoin
61,295.06
-3.98%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Halozyme Therapeutics Incorporated (HALO)

  7. Halozyme Therapeutics Incorporated (HALO) 뉴스

HALO Halozyme Therapeutics Incorporated

38.70
-0.07 (-0.18%)
최종 업데이트: 23:41:32
15분 지연
기업명 주식 심볼 시장 주식 타입
Halozyme Therapeutics Incorporated HALO 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
-0.07 -0.18% 38.70 23:41:32
개장가 저가 고가 종가 전일 종가
38.54 38.50 39.03 38.77
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
26/04/202405:45PRNUSMahesh Krishnan Elected to Halozyme's Board of Directors
23/04/202421:30PRNUSHalozyme to Report First Quarter 2024 Financial and..
05/03/202406:13EDGAR2Form PRE 14A - Other preliminary proxy statements
29/02/202408:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/02/202406:07EDGAR2Form 144 - Report of proposed sale of securities
28/02/202407:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/02/202407:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/02/202407:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/02/202406:08EDGAR2Form 144 - Report of proposed sale of securities
27/02/202422:30PRNUSHalozyme to Participate in Upcoming Investor Conferences
21/02/202408:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/02/202408:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/02/202408:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/02/202408:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/02/202406:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
21/02/202406:03EDGAR2Form 8-K - Current report
21/02/202406:01PRNUSHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL..
17/02/202407:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/02/202407:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/02/202407:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/02/202406:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/02/202406:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/02/202406:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/02/202420:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/02/202406:30PRNUSHalozyme To Report Fourth Quarter and Full Year 2023..
30/01/202406:15PRNUSHalozyme Announces Takeda Received European Commission..
24/01/202401:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
19/01/202406:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/01/202422:30PRNUSHalozyme Announces argenx Received Approval in Japan for..
18/01/202406:56EDGAR2Form 144 - Report of proposed sale of securities
17/01/202422:10EDGAR2Form 8-K - Current report
17/01/202406:26EDGAR2Form 144 - Report of proposed sale of securities
16/01/202422:15PRNUSHalozyme Announces Takeda Receives FDA Approval for HYQVIA®..
16/01/202415:15PRNUSHalozyme Announces Roche Receives European Commission..
12/01/202423:25PRNUSHalozyme to Host Investor Business Forum and Long-Term..
06/01/202406:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202309:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202306:40EDGAR2Form 144 - Report of proposed sale of securities
13/12/202306:21EDGAR2Form 144 - Report of proposed sale of securities
27/11/202322:00PRNUSHalozyme to Present at Upcoming Investor Conferences
17/11/202306:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202323:00PRNUSHalozyme Announces argenx Receives European Commission..
16/11/202306:17EDGAR2Form 144 - Report of proposed sale of securities
15/11/202306:19EDGAR2Form 144 - Report of proposed sale of securities
07/11/202306:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202306:04EDGAR2Form 8-K - Current report
07/11/202306:01PRNUSHALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING..
06/11/202321:30PRNUSHalozyme and Acumen Pharmaceuticals Enter Global..
31/10/202307:35PRNUSHalozyme To Report Third Quarter 2023 Financial and..
19/10/202320:15PRNUSPositive Topline Results Reported from Bristol Myers..

최근 히스토리

NASDAQ
HALO
Halozyme Therapeutics
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유